GERN Price / FCF | GERON CORP

GERON CORP Price-FCF Ratio

The price-to-free-cash-flow (P/FCF) ratio tells you how many dollars investors pay for each dollar of cash a company generates after paying for its capital spending. It is market capitalization divided by free cash flow over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher ratio means investors are paying more for each dollar of free cash flow; a negative ratio means the company spent more cash than it generated over those quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

GERON CORP price-fcf ratio for the quarter ending 2024-12-31 was -9.79, a change of -2.97 year-over-year.
GERON CORP price-fcf ratio for the quarter ending 2024-09-30 was -12.64, a change of -5.83 year-over-year.
GERON CORP price-fcf ratio for the quarter ending 2024-06-30 was -12.06, a change of -0.52 year-over-year.
GERON CORP price-fcf ratio for the quarter ending 2024-03-31 was -9.76, a change of -1.9 year-over-year.
GERON CORP price-fcf ratio for fiscal 2024 was -9.79, a change of -2.97 from fiscal 2023.
GERON CORP price-fcf ratio for fiscal 2023 was -6.82, a change of 0.57 from fiscal 2022.
GERON CORP price-fcf ratio for fiscal 2022 was -7.39, a change of -3.27 from fiscal 2021.
GERON CORP price-fcf ratio for fiscal 2021 was -4.12, a change of 3.24 from fiscal 2020.

Available history: 2011-09-30 to 2024-12-31
Data captured: 2024-12-31

Historical Price-FCF Ratio

Date	Price-FCF Ratio	Market capitalization	Free cash flow 12 month
2024-12-31	-9.79	$2.15B	-$219.3M
2024-09-30	-12.64	$2.74B	-$216.5M
2024-06-30	-12.06	$2.51B	-$208.59M
2024-03-31	-9.76	$1.8B	-$184.7M
2023-12-31	-6.82	$1.15B	-$168.57M
2023-09-30	-6.81	$1.11B	-$162.89M
2023-06-30	-11.53	$1.63B	-$141.61M
2023-03-31	-7.86	$1.1B	-$140.52M
2022-12-31	-7.39	$944.44M	-$127.81M
2022-09-30	-7.77	$892.09M	-$114.76M
2022-06-30	-5.42	$585.04M	-$107.94M
2022-03-31	-4.54	$440.27M	-$97.04M
2021-12-31	-4.12	$394.95M	-$95.76M
2021-09-30	-5.1	$439.22M	-$86.12M
2021-06-30	-5.71	$449.18M	-$78.64M
2021-03-31	-6.86	$503.27M	-$73.41M
2020-12-31	-7.36	$493.8M	-$67.05M
2020-09-30	-8.33	$540.21M	-$64.88M
2020-06-30	-7.19	$443.23M	-$61.67M
2020-03-31	-4.12	$238.41M	-$57.84M
2019-12-31	-6.14	$271.75M	-$44.24M
2019-09-30	-6.81	$250.6M	-$36.8M
2016-12-31	-17.88	$329.46M	-$18.43M
2016-09-30	-15.58	$359.65M	-$23.09M
2013-12-31	-15.96	$585.46M	-$36.68M
2013-09-30	-10.09	$407.35M	-$40.36M
2013-06-30	-3.74	$184.92M	-$49.4M
2013-03-31	-2.38	$132.06M	-$55.6M
2012-12-31	-3.1	$173.57M	-$56.01M
2012-09-30	-3.16	$212.15M	-$67.17M
2012-06-30	-3.2	$213.48M	-$66.81M
2012-03-31	-3.18	$212.88M	-$66.84M
2011-12-31	-2.92	$183.87M	-$63M
2011-09-30	-4.55	$263.35M	-$57.87M

Annual Price-FCF Ratio

Date	Price-FCF Ratio	Market capitalization	Free cash flow 12 month
2024-12-31	-9.79	$2.15B	-$219.3M
2023-12-31	-6.82	$1.15B	-$168.57M
2022-12-31	-7.39	$944.44M	-$127.81M
2021-12-31	-4.12	$394.95M	-$95.76M
2020-12-31	-7.36	$493.8M	-$67.05M
2019-12-31	-6.14	$271.75M	-$44.24M
2016-12-31	-17.88	$329.46M	-$18.43M
2013-12-31	-15.96	$585.46M	-$36.68M
2012-12-31	-3.1	$173.57M	-$56.01M
2011-12-31	-2.92	$183.87M	-$63M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Aclaris Therapeutics, Inc. (ACRS)	United States	$0.792B	-9.78
Olema Pharmaceuticals, Inc. (OLMA)	United States	$0.790B	-5.35
GYRE THERAPEUTICS, INC. (GYRE)	United States	$0.818B	-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)	United States	$0.823B	-17.48
Wave Life Sciences, Inc. (WVE)		$0.780B	-5.56
Obsidian Therapeutics, Inc. (OBX)	United States	$0.829B
Immix Biopharma, Inc. (IMMX)	United States	$0.837B	-18.44
Design Therapeutics, Inc. (DSGN)	United States	$0.766B	-12.78
Avalo Therapeutics, Inc. (AVTX)	United States	$0.842B	-9.74
Faeth Therapeutics, Inc. (FTH)	United States	$0.750B